Analyst Reco. Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq Other stock markets 04:00:06 2024-04-23 pm EDT			5-day change	1st Jan Change
33.95 ^USD	-2.72%		+1.53%	-17.52%

Apr. 15	H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating	MT
Apr. 12	HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating	Apr. 15	MT
HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating	Apr. 12	MT
Wedbush Adjusts Arvinas' Price Target to $57 From $59, Keeps Outperform Rating	Apr. 11	MT
Barclays Adjusts Arvinas' Price Target to $60 From $26, Maintains Overweight Rating	Feb. 29	MT
BMO Capital Adjusts Arvinas' Price Target to $90 From $89, Maintains Outperform Rating	Feb. 28	MT
Oppenheimer Adjusts Arvinas Price Target to $80 From $95, Maintains Outperform Rating	Feb. 28	MT
Wedbush Raises Arvinas' PT to $59 From $33, Sees 'Strong' Set Up in 2024; Keeps Outperform Rating	Feb. 28	MT
Citigroup Downgrades Arvinas to Neutral From Buy, Adjusts Price Target to $55 From $36	Feb. 14	MT
Wells Fargo Upgrades Arvinas to Overweight From Equalweight, Price Target to $63	Dec. 19	MT
Jefferies Upgrades Arvinas to Buy From Hold, Raises Price Target to $40 From $32	Dec. 06	MT
Wedbush Raises Arvinas' PT to $33 From $24, Says Vepdegestrant Combined With Palbociclib for Potential Breast Cancer Treatment Continues to Impress; Maintains Outperform Rating	Dec. 06	MT
Guggenheim Upgrades Arvinas to Buy From Neutral, Price Target is $40	Nov. 20	MT
Morgan Stanley Adjusts Price Target on Arvinas to $20 From $32, Reiterates Equalweight Rating	Nov. 13	MT
Citigroup Adjusts Arvinas' Price Target to $36 From $72, Maintains Buy Rating	23-10-24	MT
Barclays Adjusts Price Target on Arvinas to $26 From $39, Keeps Overweight Rating	23-10-24	MT
Wedbush Upgrades Arvinas to Outperform From Neutral After Recent Sell-Off, Notes Plans to De-Prioritize Bavdegalutamide in Favor of ARV-766; Adjusts PT to $24 From $27	23-10-23	MT
Citigroup Adjusts Arvinas Price Target to $72 From $77, Maintains Buy Rating	23-08-21	MT
Morgan Stanley Adjusts Price Target on Arvinas to $32 From $35, Maintains Equal-Weight Rating	23-08-14	MT
Barclays Lowers Price Target on Arvinas to $39 From $70, Maintains Overweight Rating	23-08-09	MT
UBS Adjusts Arvinas Price Target to $90 From $151, Maintains Buy Rating	23-05-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arvinas, Inc.

Equities

ARVN

US04335A1051

Analyst Reco.

Filters